Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
CA 2390412 A1 · Owner: Biogen Idec Inc. · Inventors: Hanna, Nabil; Hariharan, Kandasamy
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention discloses compositions, combination therapies and methods of treating B-cell lymphomas and leukemias as well as other CD40+ malignancies. , The primary active agent of the composition is an anti-CD40L antibody or other CD40L antagonist that inhibits CD40-CD40L interaction. Compositions may additionally contain or utilize any one or more of the following in combination for the treatment of said disease: anti-CD20 antibodies chemotherapeutic agents, chemotherapy cocktails and radiotherapy.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 6, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 6, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 6, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.